This site is intended for health professionals only

Published on 22 June 2007

Share this story:

RELATED ARTICLES
Denosumab for menopausal and cancer-related bone loss
Patient knowledge of colorectal cancer therapy side-effects
Understanding compassionate-use programmes
ECCMID: Developments in invasive fungal disease
ECCO President’s preview of the Congress

US go-ahead for Exforge

teaser

↓Article continues below this sponsored advert↓
↑Advertisement↑

Novartis has received US approval for Exforge






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
Share this story:

RELATED ARTICLES
Researchers pioneer liquid aspirin
NHS pharmaceutical guidance hailed
First European study of Tresiba® shows improved blood glucose control and reduced hypoglycaemia risk
EU approves meningococcal vaccine
Extending rivaroxaban treatment course reduces risk of recurrent venous thromboembolism
FOLLOW US

IMPORTANT LINKS

MORE FROM COGORA

© Cogora 2025
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
x